Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.

[1]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[2]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[3]  G. Sauter,et al.  Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence , 2013, Modern Pathology.

[4]  G. Sauter,et al.  Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers , 2013, International journal of cancer.

[5]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[6]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[7]  Lu Wu,et al.  Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Chin-Lee Wu,et al.  Expression of CD147 is associated with prostate cancer progression , 2012, International journal of cancer.

[9]  N. Fineberg,et al.  Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma , 2011, Molecular Cancer Therapeutics.

[10]  Tim Beißbarth,et al.  TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.

[11]  Chin-Lee Wu,et al.  Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.

[12]  A. Haese*,et al.  The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. , 2011, International journal of oncology.

[13]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[14]  R. Reis,et al.  Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer , 2011, BMC Cancer.

[15]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[16]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[17]  O. Kallioniemi,et al.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.

[18]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[19]  J. Zou,et al.  Expression and clinical significance of CD147 in genitourinary carcinomas. , 2010, The Journal of surgical research.

[20]  G. Sauter,et al.  Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.

[21]  J. Zou,et al.  CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer , 2009, Pathology & Oncology Research.

[22]  Yang Zhang,et al.  [Expression and significance of CD147 protein in prostate cancer]. , 2009, Zhonghua yi xue za zhi.

[23]  E. Rosenthal,et al.  Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer , 2009, Clinical Cancer Research.

[24]  G. Jenster,et al.  Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.

[25]  Martin Schostak,et al.  Expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European urology.

[26]  G. Sauter,et al.  Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients , 2008, Clinical Cancer Research.

[27]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[28]  W. Zhong,et al.  CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer , 2008, Oncology.

[29]  B. Trask,et al.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.

[30]  Yong Li,et al.  The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression , 2008, Cancer Immunology, Immunotherapy.

[31]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[32]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[33]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[34]  G. Sauter,et al.  High incidence of EMMPRIN expression in human tumors , 2006, International journal of cancer.

[35]  P. Span,et al.  Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. , 2006, Cancer letters.

[36]  Jing Xu,et al.  Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. , 2006, International journal of radiation oncology, biology, physics.

[37]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[38]  Yi Tang,et al.  Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.

[39]  M. Urashima,et al.  CD147 and matrix metalloproteinase‐2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma , 2004, Cancer.

[40]  Rongsong Li,et al.  Emmprin Promotes Anchorage-Independent Growth in Human Mammary Carcinoma Cells by Stimulating Hyaluronan Production , 2004, Cancer Research.

[41]  Yi Tang,et al.  Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. , 2004, Molecular cancer research : MCR.

[42]  T. Kanekura,et al.  Basigin (cd147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts , 2002, International journal of cancer.

[43]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[44]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[45]  Y. Okada,et al.  Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. , 2000, Cancer letters.

[46]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[47]  B. Toole,et al.  Stimulation of Matrix Metalloproteinase Production by Recombinant Extracellular Matrix Metalloproteinase Inducer from Transfected Chinese Hamster Ovary Cells* , 1997, The Journal of Biological Chemistry.

[48]  H. Moch,et al.  Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.

[49]  H. Guo,et al.  The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. , 1995, Cancer research.

[50]  G. Sauter,et al.  Marked heterogeneity of ERG expression in large primary prostate cancers , 2013, Modern Pathology.

[51]  K. Pienta,et al.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.

[52]  A. Jemal,et al.  Global Cancer Statistics , 2011 .